Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...

How is it possible to build new forms of life, like bacteria that glow in the dark or yeast that smells like bananas? In this ...

The intricate process of duplicating genetic information, referred to as DNA replication, lies at the heart of the transmission of life from one cell to another and from one organism to the next. This ...

Resting brain stem cells hardly differ from normal astrocytes, which support the nerve cells in the brain. How can almost identical cells perform such different functions? The key lies in the ...

Researchers discovered that embryos must clear maternal mRNAs to develop properly. When cleanup fails, it causes aberrant ...

"Manipulating the H3.3 pathway may provide a way to completely wipe a cell's ‘memory’ and produce a truly pluripotent cell,” geneticist Steven Henikoff, from the Fred Hutchinson Cancer Research Center ...

Every fall, millions of Americans get their annual flu shots—and while they are at it, they now also get their annual Covid-19 boosters. Already, these shots seem routine; it is easy to forget that ...

Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at ...

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc.